Vor Bio to Participate in the 46th Annual TD Cowen Health Care Conference

BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will be presenting and hosting 1x1 investor meetings at the 46th Annual TD Cowen Health Care Conference in Boston, MA. Presentation: Monday, March 2, 2026 at 9:50am – 10:20 am ETLocation: Regis A live webcast and archived replay of the presentation will be remain available for a period of 90 days on the Company's website at: https://ir.vorbio.com/events-presentations/ About Vor Bio Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases.

GlobeNewsWire • Feb 23, 2026

Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference

BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will be presenting and hosting 1x1 investor meetings at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

GlobeNewsWire • Jan 6, 2026

Vor Bio Appoints RA Capital's Andrew Levin, M.D., Ph.D., and Forbion's Wouter Joustra to Board of Directors

BOSTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the appointment of Andrew Levin, M.D., Ph.D., Partner at RA Capital Management, and Wouter Joustra, General Partner at Forbion, to its Board of Directors. Their appointments follow the Company's recently announced $150M PIPE financing, which included participation from both investors.

GlobeNewsWire • Dec 23, 2025

Vor Bio Announces $150 Million Private Placement

BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a securities purchase agreement to sell 13,876,032 shares of its common stock at a price of $10.81 per share to a select group of institutional and accredited healthcare specialist investors in a private placement. Vor Bio anticipates the gross proceeds from the private placement to be approximately $150 million, before deducting any offering-related expenses. Vor Bio did not engage a placement agent in connection with the private placement. The private placement is expected to close on or about December 18, 2025, subject to the satisfaction of customary closing conditions.

GlobeNewsWire • Dec 15, 2025

Vor Biopharma (VOR) Upgraded to Buy: Here's What You Should Know

Vor Biopharma (VOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research • Nov 25, 2025

Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Multiple Late-Stage Data Readouts Reinforce Telitacicept's Broad Potential Across Autoimmune Diseases Expansion of Executive Leadership and Board Strengthens Global Development Capabilities

GlobeNewsWire • Nov 13, 2025

Vor Biopharma Secures $100 Million Offering After Reporting Efficacy In Kidney Disease Trial

Vor Biopharma Inc. (NASDAQ:VOR) on Tuesday priced an underwritten public offering of 10 million shares at $10.00 per share.

Benzinga • Nov 11, 2025

Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock

BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR) (Vor Bio), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced that it has commenced an underwritten public offering of $100 million of shares of its common stock. In addition, Vor Bio intends to grant the underwriters a 30-day option to purchase up to an additional $15 million of shares of its common stock at the public offering price, less underwriting discounts and commissions.

GlobeNewsWire • Nov 10, 2025

Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock

BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $10.00 per share. The gross proceeds from the offering are expected to be $100 million, before deducting the underwriting discounts and commissions and offering expenses. The offering is expected to close on or about November 12, 2025, subject to customary closing conditions. In addition, Vor Bio has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares are being sold by Vor Bio.

GlobeNewsWire • Nov 11, 2025

Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China

Treatment with telitacicept for 39 weeks resulted in a rapid, clinically meaningful, and statistically significant reduction in proteinuria, with a favorable safety profile

GlobeNewsWire • Nov 8, 2025